Los Angeles Capital Management LLC Acquires Shares of 11,760 Elanco Animal Health Incorporated (NYSE:ELAN)

Los Angeles Capital Management LLC purchased a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 11,760 shares of the company’s stock, valued at approximately $170,000.

Other large investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Elanco Animal Health in the first quarter worth approximately $1,226,000. Vanguard Group Inc. grew its stake in shares of Elanco Animal Health by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock worth $737,083,000 after acquiring an additional 467,196 shares during the period. Bank of Nova Scotia bought a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $4,004,000. Wolf Hill Capital Management LP bought a new stake in shares of Elanco Animal Health in the fourth quarter worth approximately $20,683,000. Finally, Jupiter Asset Management Ltd. bought a new stake in shares of Elanco Animal Health in the first quarter worth approximately $4,956,000. 97.48% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ELAN shares. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. Barclays dropped their price objective on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.57.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $14.47 on Monday. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. Elanco Animal Health Incorporated has a 1-year low of $8.52 and a 1-year high of $18.80. The company has a market capitalization of $7.15 billion, a P/E ratio of -5.46, a P/E/G ratio of 1.44 and a beta of 1.40. The firm’s 50 day simple moving average is $13.87 and its two-hundred day simple moving average is $15.20.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same quarter in the previous year, the firm earned $0.18 earnings per share. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. Research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In related news, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now owns 81,094 shares in the company, valued at $1,204,245.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was purchased at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now owns 81,094 shares in the company, valued at $1,204,245.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the transaction, the chief executive officer now owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The disclosure for this purchase can be found here. Insiders own 0.57% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.